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Dear Editor,  
A 54-year-old man, with good past health, was diagnosed to have International Stage III, IgG 
myeloma in Dec, 2006 with IgG M-protein measuring 116g/L, serum albumin 22g/L (normal: 
40-50g/L) β2-microglobulin of 9.25 mol/L and 56% plasma cell infiltration of the bone marrow 
at diagnosis. He achieved a partial remission with a 83% reduction of M-protein to 15g/L after 
the induction with the staged approach, [1,2] which comprised three cycles of VAD (vincristine, 
adriamycin and dexamethasone), followed by 4 cycles of salvage VTD (bortezomib, thalidomide 
and dexamethasone) in patients failing a ≥75% reduction in M-protein level after VAD. He 
achieved very good partial response (VGPR, i.e. >90% reduction of M-protein), and 
immunofixation-negative complete remission (CR) at 3 and 6 months after autologous stem cell 
transplantation (ASCT) in July, 2007.  He was entirely asymptomatic until May 2012 when he 
complained of a painless left cervical lymph node. Excisional lymph node biopsy showed 
enlarged lymph node with effaced nodal architecture, which was replaced by a mixed 
inflammatory infiltrate with scattered large-sized classical Reed-Sternberg cells. (Figure 1A, 
hematoxylin and eosin, x 200) The Reed-Sternberg cells were positive for Epstein-Barr encoded 
early RNA (EBER), (Figure 1B, x 200) and expressed CD30, (Figure 1C, x 400) and CD15 
(Figure 1D, x 400). Finally, clonality study by polymerase chain reaction for immunoglobulin 
heavy chain (IgH) gene showed clonal IgH gene rearrangement in the diagnostic myeloma (MM) 
but not Hodgkin’s lymphoma (HL) sample. (Figure 2). Therefore, the overall features were 
consistent with mixed cellularity classical Hodgkin’s lymphoma (HL) with no evidence of 
plasma cell neoplasm.  
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 Staging combined positron-emission tomography-computed tomography (PET-CT) scan 
showed generalized lymphadenopathy in cervical, mediastinal, abdominal and pelvic regions 
with maximum standardized uptake value (SUVmax) ranging from 3.8 to 15.5. Bilateral trephine 
biopsies revealed no plasma cells or lymphoma infiltration. Therefore, this patient had Ann 
Arbor Stage IIIA Classical HL during CR of myeloma.  He was planned for 6 cycles of ABVD. 
Interim PET-CT assessment showed CR after 3 cycles of ABVD.  
Myeloma is a neoplastic proliferation of mature, post-germinal center B-lymphocytes. 
Recent combination of novel agents induction followed by ASCT has markedly improved CR 
rates and survivals. The advent of the staged approach aimed to reduce the expensive use of 
bortezomib upfront while preserving CR rate. [1,2] Second primary malignancies (SPM) have 
been reported in myeloma, in particular in the setting of ASCT, after which therapy-related 
myelodysplastic syndrome or therapy-related acute myeloid leukemia may occur after high-dose 
melphalan. 
Recently, SPM including lymphoid malignancies have been reported in transplant-
eligible myeloma patients receiving lenalidomide maintenance therapy. [3,4] In the French study, 
26 SPM occurred in the lenalidomide maintenance arm compared with 11 SPM in the placebo 
arm (p=0.002).[3] Of these, 13 were hematological cancers, which comprised MDS/AML (N=5), 
ALL (N=3), NHL (N=1) and HL (N=4). [3] Similarly, an increased risk of SPM including 
hematological cancers of lymphoid origin, with ALL (N=5) and HL (N=1) compared with 
absence of these lymphoid malignancies in the placebo group,[4] has also been shown in another 
trial in which transplant-eligible myeloma patients were randomized to receive lenalidomide or 
placebo. Moreover, in a large series of 589 consecutive myeloma patients between 1997 and 
2008, [5] thirteen patients developed a hematological malignancy. Apart from 6 cases of 
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MDS/AML, which occurred at more than 50 months after the diagnosis of myeloma, one patient 
had concomitant HL with myeloma. Therefore, sequential Hodgkin’s lymphoma in myeloma 
may occur even in the absence of prior treatment with lenalidomide.    
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Legend 
Figure 1. Excisional lymph node biopsy showed enlarged lymph node with effaced nodal 
architecture, which was replaced by a mixed inflammatory infiltrate with scattered large-sized 
classical Reed-Sternberg cells with large-sized, mirror-image vesicular nuclei and prominent 
eosinohilic nucleoli in addition to Reed-Sternberg cell variants. (Figure 1A, hematoxylin and 
eosin, x 200) In-situ hybridization for Epstein-Barr encoded early RNA (EBER) showed that the 
Reed-Sternberg cells were positive. (Figure 1B, x 200) Immunohistochemical stains showed that 
the Reed-Sternberg cells were positive for CD30, (Figure 1C, x 400) with a proportion positive 
for CD15 (Figure 1D, x 400) 
Figure 2. Polymerase chain reaction for immunoglobulin heavy chain (IgH) gene showed clonal 
IgH gene rearrangement in the diagnostic myeloma (MM) in addition to the positive control (P) 
but not Hodgkin’s lymphoma (HL) sample, negative control or reagent blank. (Figure 2A). In 
addition, positive PCR for β-hemoglobin confirmed integrity of DNA samples (Figure 2B) 
 
